Interview with Sophie Kornowski-Bonnet, President, France, Roche France
Roche has a long history in France and currently enjoys a higher position than its worldwide ranking. Can you elaborate on the importance of this market for the group overall?…
Address: 52, avenue du Parc, Neuilly sur Seine 92521,France
Tel: +33 (0)1 46 40 50 00
Web: http://www.roche.fr/portal/roche-fr/index_
Leading at the hospital, Roche is the 3rd largest pharmaceutical companies in France in 2008.
The Roche Group is present in France through two entities:
• Roche SAS, specializes in prescription drugs
• Roche Diagnostics, the French biological diagnostics
• Total turnover: € 1 654.2 million
• New investments: 30.5 million €
• R & D Spending: 26.1 M €
• Total staff: 1 767 people
Roche offers patients and the medical prescription drugs in particular therapeutic areas of Cancer
Anemia
Transplantation
Virology
Rheumatology
Autoimmune Diseases
Metabolism Disorders
Roche has a long history in France and currently enjoys a higher position than its worldwide ranking. Can you elaborate on the importance of this market for the group overall?…
Vincent Pont, president of Laboratoire Arrow, explains the company’s history, its collaboration with Aurobindo, the Indian generic pharmaceuticals group, the company’s unique positioning as a leader in the generic hospital…
Bertrand de Lavenne, general manager of Mylan France, explains how the affiliate is positioned within the group’s operations and how the Mylan strategy is to be a key actor in…
Christophe Lala, general manager of western Europe for GE Healthcare offers an overview of the current dynamics impacting the French healthcare landscape – namely a shift in structure around care…
Martine Claret of Horus Pharma – a family-owned ophthalmology pharmaceutical company established in 2003 and based in Nice – discusses the highly regulated and competitive ophthalmology market, the company’s remarkable…
Faten Hidri, VP for Higher Education & Research in the Paris Region (Ile de France), discusses the vital role of academic research and the life sciences in her region and…
Pascal Girin, CEO of BALT, shares how his rich career in neurovascular medical technology helped him to transform the company from a small R&D pure player into an international market…
Pascal Brière, president of Biogaran, the leading French domestic player in generics, reflects on the development of the generic market since the 1999 Generic Substitution Act. Brière goes on to…
Bertrand Sohier, VP and general manager business and administration of Parexel France discusses the latest trends impacting the clinical research environment of the country, gives insight on the strategies the…
Michel Spagnol, chairman and CEO of Novasep, a robust French CDMO, shares his insights on the key global trends that are shaping today’s CMDO sector – particularly the emerging significance…
France is rediscovering its mojo. After a period of relative stagnation, the country’s highly strategic USD 65 billion healthcare and life sciences market is once again an attractive investment proposition.…
Jean-Marc Grognet, general manager of Genopole, France’s leading biotechnology cluster, explains the organization’s unique triangular structure with the corner points of the cluster being higher education, research, and industry. Grognet…
Jean-Louis Anspach, general manager of Teva France, elaborates on the affiliate’s transitional restructuring period as they make a turnaround effort in the face of group-wide challenges. Anspach goes on to…
See our Cookie Privacy Policy Here
